These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23890909)

  • 1. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison.
    Fusaro M; Cassese S; Ndrepepa G; King LA; Tada T; Ott I; Kastrati A
    Int J Cardiol; 2013 Oct; 168(4):4002-9. PubMed ID: 23890909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Ott I; Ndrepepa G; Nerad M; Kastrati A; Fusaro M
    Circ Cardiovasc Interv; 2012 Aug; 5(4):582-9. PubMed ID: 22851526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries.
    Kayssi A; Al-Jundi W; Papia G; Kucey DS; Forbes T; Rajan DK; Neville R; Dueck AD
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012510. PubMed ID: 30684445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis.
    Wu R; Li Z; Wang M; Chang G; Yao C; Wang S
    Int J Surg; 2017 Jun; 42():72-82. PubMed ID: 28461145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery.
    Katsanos K; Spiliopoulos S; Karunanithy N; Krokidis M; Sabharwal T; Taylor P
    J Vasc Surg; 2014 Apr; 59(4):1123-1133.e8. PubMed ID: 24661896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study.
    Wöhrle J; Zadura M; Möbius-Winkler S; Leschke M; Opitz C; Ahmed W; Barragan P; Simon JP; Cassel G; Scheller B
    J Am Coll Cardiol; 2012 Oct; 60(18):1733-8. PubMed ID: 23040575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel density and clinical efficacy of drug-coated balloon angioplasty for femoropopliteal artery disease: meta-analysis and adjusted indirect comparison of 20 randomised trials.
    Cassese S; Ndrepepa G; Fusaro M; Kufner S; Xhepa E; Fusaro M
    EuroIntervention; 2019 Aug; 15(6):e560-e562. PubMed ID: 30277463
    [No Abstract]   [Full Text] [Related]  

  • 11. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
    Scheinert D; Schulte KL; Zeller T; Lammer J; Tepe G
    J Endovasc Ther; 2015 Feb; 22(1):14-21. PubMed ID: 25775674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
    Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis of randomized controlled trials.
    Acin F; de Haro J; Bleda S; Varela C; Esparza L
    J Endovasc Ther; 2012 Oct; 19(5):585-95. PubMed ID: 23046322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
    Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
    Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
    Werk M; Langner S; Reinkensmeier B; Boettcher HF; Tepe G; Dietz U; Hosten N; Hamm B; Speck U; Ricke J
    Circulation; 2008 Sep; 118(13):1358-65. PubMed ID: 18779447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics.
    Du X; Wang F; Wu DM; Zhang MH; Jia X; Zhang JW; Zhuang BX; Zhao Y; Guo PF; Bi W; Fu WG; Guo W; Wang SM
    Medicine (Baltimore); 2019 Mar; 98(13):e14840. PubMed ID: 30921183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study.
    Rittger H; Brachmann J; Sinha AM; Waliszewski M; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Breithardt OA; Schmidt M; Zimmermann S; Lonke S; von Cranach M; Nguyen TV; Daniel WG; Wöhrle J
    J Am Coll Cardiol; 2012 Apr; 59(15):1377-82. PubMed ID: 22386286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-coated balloon angioplasty versus balloon angioplasty for treating patients with in-stent restenosis in the femoropopliteal artery: A meta-analysis.
    Cao S; He T; Xie J; Feng H; Liu K; Qu B; Wu X
    Medicine (Baltimore); 2021 Apr; 100(16):e25599. PubMed ID: 33879723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease.
    Rocha-Singh KJ; Jaff MR; Crabtree TR; Bloch DA; Ansel G;
    Catheter Cardiovasc Interv; 2007 May; 69(6):910-9. PubMed ID: 17377972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.